Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag080 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Alexy Inciarte und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Drug Resistance, Viral, HIV Infections, HIV-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: ViiV.
Abstract (Originalsprache)
Objectives
To assess the prevalence of transmitted drug resistance mutations (TDRMs) and the impact of pre-existing resistance mutations, including minority variants, on virological response in ART-naïve individuals initiating dolutegravir-based triple therapy using next-generation sequencing (GRT-NGS).
Methods
A multicentre, retrospective cohort study was conducted including ART-naïve individuals who started a dolutegravir-3DR between 2015 and 2019. Baseline GRT-NGS Illumina®, covering RT, PR and IN genes identified primary (P-DRM) and secondary/polymorphic (S/p-DRM) mutations in high-abundance drug resistance variants (HA-DRVs; ≥20%) and low-abundance drug resistance variants (LA-DRVs; 1%–19%). Virological failure (VF) was defined as two consecutive HIV-1 RNA ≥ 50 copies/mL. Virological response was assessed at Weeks 48 and 96.
Results
Of 326 participants, 86% were male and 72% were MSM; 78% received DTG/ABC/3TC and 22% TDF/FTC + DTG. At least one TDRM was detected in 24% and any DRM in 48% of subjects. Virological suppression was achieved in 76% by intention-to-treat (ITT), 97% on-treatment (OT) and 56% (ITT), 94% (ITT) at Weeks 48 and 96, respectively. VF occurred in 11 subjects (3.4%), mostly within 48 weeks, all with low-level viraemia (<1000 copies/mL; 8 < 200 copies/mL) and no emergent of new DRM in HA-DRVs with phenotypic impact. Among those with pre-existing DRM, including 36 P-HA-DRVs, 79 S/p-HA-DRVs, 57 P-LA-DRVs and 45 S/P-LA-DRVs, no significant association with VF was observed.
Conclusions
Our findings indicate that pre-existing IN and RT DRM, including low-abundance and secondary/polymorphic variants, did not compromise the virological efficacy of dolutegravir-based triple therapy in ART-naïve individuals, supporting the high resistance barrier of dolutegravir and the lack of need for baseline resistance testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Clínic de Barcelona, Barcelona, Spain.
- Institut d'Investigacions Mèdiques August Pi i Sunyer (IDIBAPS).
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
- Hospital Universitario de Canarias, Spain.
- Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
- Consorcio Hospital General Universitario, Valencia, Spain.
ORCID-Profile: José R Santos, Elisa de Lazzari, Miguel Garcia Del Toro, Esteban Martínez, Roger Paredes, José Luis Blanco
Förderung
- ViiV
Zitieren
APA
Inciarte, A., Berrocal, L., Santos, J. R., Aleman, M. R., Curran, A., Medina Gonzalez, R., Bernal, S., de Lazzari, E., Garcia Del Toro, M., Raventós, B., Lopez Lirola, A. M., Martínez, E., Paredes, R., Blanco, J. L., & Integrasa Marginal Study Group Team Group (2026). Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag080
Vancouver
Inciarte A, Berrocal L, Santos JR, Aleman MR, Curran A, Medina Gonzalez R, et al. Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag080
BibTeX
@article{Inciarte2026,
author = {Inciarte, Alexy and Berrocal, Leire and Santos, José R and Aleman, Maria R and Curran, Adrian and Medina Gonzalez, Rafael and Bernal, Samuel and de Lazzari, Elisa and Garcia Del Toro, Miguel and Raventós, Berta and Lopez Lirola, Ana M and Martínez, Esteban and Paredes, Roger and Blanco, José Luis and Integrasa Marginal Study Group Team Group, Integrasa Marginal Study Group Team Group},
title = {Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag080}
}
EUVIMED